These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32878735)

  • 1. Promoting the ethical use of safe and effective cell-based products: the Andalusian plan on regenerative medicine.
    Cuende N; Álvarez-Márquez AJ; Díaz-Aunión C; Castro P; Huet J; Pérez-Villares JM
    Cytotherapy; 2020 Dec; 22(12):712-717. PubMed ID: 32878735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
    Takashima K; Morrison M; Minari J
    Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products.
    Ikonomou L; Cuende N; Forte M; Grilley BJ; Levine AD; Munsie M; Rasko JEJ; Turner L; Bidkhori HR; Ciccocioppo R; Grignon F; Srivastava A; Weiss DJ; Zettler P; Levine BL;
    Cytotherapy; 2023 Sep; 25(9):920-929. PubMed ID: 37517865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating regenerative medicine: the Japanese experiment in ethics and regulation.
    Lysaght T
    Regen Med; 2017 Sep; 12(6):657-668. PubMed ID: 28976822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation.
    Chan S
    Regen Med; 2017 Oct; 12(7):839-851. PubMed ID: 29119870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
    Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
    Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials.
    Kleiderman E; Boily A; Hasilo C; Knoppers BM
    Stem Cell Res Ther; 2018 Nov; 9(1):307. PubMed ID: 30409192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell research and therapies in Argentina: the legal and regulatory approach.
    de Arzuaga FC
    Stem Cells Dev; 2013 Dec; 22 Suppl 1():40-3. PubMed ID: 24304074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Navani A; Manchikanti L; Albers SL; Latchaw RE; Sanapati J; Kaye AD; Atluri S; Jordan S; Gupta A; Cedeno D; Vallejo A; Fellows B; Knezevic NN; Pappolla M; Diwan S; Trescot AM; Soin A; Kaye AM; Aydin SM; Calodney AK; Candido KD; Bakshi S; Benyamin RM; Vallejo R; Watanabe A; Beall D; Stitik TP; Foye PM; Helander EM; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S1-S74. PubMed ID: 30717500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
    Okada K; Sato Y; Sugiyama D; Sawa Y
    Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
    Fujita Y; Kawamoto A
    Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Court of Human Rights' ruling on unproven stem cell therapies: a missed opportunity?
    Rial-Sebbag E; Blasimme A
    Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):39-43. PubMed ID: 25457960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study.
    Chavez J; Shah NA; Ruoss S; Cuomo RE; Ward SR; Mackey TK
    Stem Cell Res Ther; 2021 Mar; 12(1):189. PubMed ID: 33736697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ethical, legal and social issues on regenerative medicine].
    Tsukata Y
    Nihon Geka Gakkai Zasshi; 2004 Aug; 105(8):435-9. PubMed ID: 15373219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ethical, legal and social issues in regenerative medicine].
    Ida R
    Nihon Rinsho; 2008 May; 66(5):991-6. PubMed ID: 18464522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model.
    Viswanathan S; Rao M; Keating A; Srivastava A
    Stem Cells Transl Med; 2013 Aug; 2(8):607-13. PubMed ID: 23836804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.